Table 2.
Illness severity, risk factors, COVID-19-associated coagulopathy, and outcomes
| Therapeutic dose (N = 19) | Intermediate dose (N = 23) | p value | |
|---|---|---|---|
| Illness severity | |||
| Apache II score | 5 (3–9) | 7 (5–10) | 0.526 |
| COVID-19 severity | |||
| Mild | 0 (0) | 2 (8.7) | 0.065 |
| Moderate | 9 (47.4) | 16 (69.6) | |
| Severe | 4 (21.1) | 4 (17.4) | |
| Critical | 6 (31.6) | 1 (4.3) | |
| DVT risk factors | |||
| History of thrombophilia | 0 (0) | 0 (0) | − |
| Critical illness | 11 (57.9) | 7 (30.4) | 0.073 |
| Active malignancy | 0 (0) | 4 (17.4) | 0.114 |
| Acute paresis | 1 (5.3) | 1 (4.3) | >0.999 |
| Immobility | 14 (73.7) | 11 (47.8) | 0.089 |
| Acute infections | 19 (100) | 23 (100) | − |
| Previous VTE | 0 (0) | 0 (0) | − |
| Age >60 years | 8 (42.1) | 7 (30.4) | 0.432 |
| Inflammatory data | |||
| CRP | 135 (95–150) | 55 (16–150) | 0.246 |
| ESR | 33.5 (7.25–60.25) | 27.5 (4.75–70.25) | 0.769 |
| LDH | 908 (530.5–1,075) | 715 (463–985.75) | 0.503 |
| Troponin | 17 (5.45–68.5) | 4.5 (1.5–36.25) | 0.083 |
| IL-6, pg/mL | 110 (27.9–172) | 20 (9.87–40.92) | 0.009 |
| D-Dimer | 1,036.5 (826.5–2,303.5) | 460 (259.25–721.5) | 0.009 |
| PCT | 0.11 (0.07–0.23) | 0.07 (0.04–0.09) | 0.157 |
| Outcomes | |||
| DVT | 5 (26.3) | 4 (17.4) | 0.707 |
| Central line | 1 (5.3) | 1 (4.30) | >0.999 |
| Sepsis | 1 (5.3) | 1 (4.3) | >0.999 |
| RRT | 0 (0) | 0 (0) | - |
| Vasopressor | 5 (26.3) | 2 (8.7) | 0.214 |
| Final status | |||
| Death | 4 (21.1) | 1 (4.3) | 0.158 |
| Discharge | 10 (52.6) | 18 (78.3) | 0.079 |
| ICU length of stay >7 days | 5 (26.3) | 4 (17.4) | 0.707 |
RRT, renal replacement therapy; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; LDH, lactate dehydrogenase; PCT, procalcitonin. Values are shown as median (Q1-Q3) and frequency (percentage).